12 results about "Hemopexin" patented technology

Hemopexin, salubrinal, aurothioglucose, and nitrite find uses in treating pulmonary injury from several causes, alone and in combination. Methods of treatment, methods of prevention, and pharmaceutical compositions are provided with those components.

A cell-free method for synthesizing a hemoprotein or peptide chain. The method comprises: adding a DNA or RNA template encoding a heme-binding protein or peptide chain to a cell-free in-vitro synthesis system so as to synthesize the heme-free form of the heme-binding protein in vitro; and incubating the heme with a binding system containing the heme-binding protein or peptide chain for a predetermined period of time so as to produce a hemoprotein or peptide chain bound to the heme. The method does not require modifications to a strain and fermentation broth, involves simple production, and has universal applicability.

The present invention relates to haptoglobin (Hp), and optionally hemopexin (Hx), for use in the treatment of traumatic brain injury (TBI) and in particular in the treatment or prevention of a secondary brain injury in a subject suffering from a TBI.

The invention discloses application of serum alpha-non-red blood cell ghost protein 1 in preparation of drugs for diagnosing heart light chain amyloidosis diseases, and belongs to the technical field of biological medicines. The serum SPTAN1 protein is used for preparing the medicine for diagnosing the heart light-chain amyloidosis disease, the medicine is limited to be an enzyme linked immunosorbent assay kit, and the kit comprises an antibody of the SPTAN1 protein and further comprises a pre-coated plate, a standard substance, a coating buffer solution, a sample diluent, a confining liquid, horse radish peroxidase, an eluent and a color developing agent. The concentration of the SPTAN1 protein in the serum is measured through an enzyme linked immunosorbent assay kit, and early diagnosis of the heart AL amyloidosis disease is carried out. The invention provides a novel, efficient and sensitive biomarker, namely the serum SPTAN1 protein, early diagnosis of heart AL amyloidosis is realized by detecting the concentration of the SPTAN1 protein in serum, and the serum SPTAN1 protein has an important clinical application prospect.

The present disclosure relates generally to heme-binding proteins and compositions thereof, and their use in the treatment of ischemia-reperfusion injury, in particular ischemia-reperfusion injury-mediated inflammation.

The invention provides a method for cell-free synthesis of heme protein or peptide chain, which is characterized by comprising the following steps: adding a DNA (Deoxyribose Nucleic Acid) or RNA (Ribonucleic Acid) template for coding the heme binding protein or peptide chain into a cell-free in-vitro synthesis system for in-vitro synthesis of heme-free heme binding protein; the heme is incubated with a binding system containing the heme binding protein or peptide chain for a predetermined time to produce a heme protein or peptide chain to which the heme is bound. According to the present invention, the expression of the heme protein can be completed only by providing any DNA or RNA template of the target protein of which the code can be combined with the heme, adding the DNA or RNA template to the cell-free system, and incubating with the heme, the change of the bacterial strain and the fermentation broth is not required, the production is simple, and the method has general applicability.

Disclosed are methods for managing a treatment in an adult individual having systemic lupus erythematosus (SLE) undergoing therapy for lupus nephritis. In aspects, the method comprises detecting a level of each of neutrophil gelatinase associated lipocalin (NGAL), kidney injury molecule 1 (KIM-1), monocyte chemotactic protein 1 (MCP-1), adiponectin, hemopexin, and ceruloplasmin in a urine sample obtained from the individual, the levels of which are used to determine a score at a first time point and a second time point. Whether the individual is responding to the therapy, in particular an induction phase of a therapy, is determined based on a comparison of the first and second score. The therapy may then be continued or adjusted based on that determination.

This document relates to materials and methods for the production of protein. In one aspect, this document provides a first exogenous nucleic acid construct including a nucleotide sequence encoding an aminolevulinate synthase (ALAS) protein operably linked to a first promoter element, wherein the ALAS includes at least a first heme responsive motif (HRM), and wherein the ALAS includes a mutation in the first HRM, and a second exogenous nucleic acid construct comprising a nucleotide sequence encoding a heme-binding protein, wherein the second exogenous nucleic acid construct including a nucleotide sequence encoding the heme-binding protein is operably linked to the first promoter element or is operably linked to a second promoter element.

Disclosed herein is a method for purifying proteins, particularly hemopexin, comprising passing a solution containing hemopexin and other proteins through a mixed-mode cation exchange chromatography resin under conditions that promote selective binding of hemopexin to the resin, and eluting the bound hemopexin from the resin. The disclosure also extends to compositions containing purified hemopexin and uses thereof.

The present invention relates generally to a stable liquid formulation of purified hemopexin comprising: (a) a hemopexin content of at least 50 mg / mL; (b) at least 15 mM phosphate buffer; (c) a pH from 5.8 to 8; and (d) at least 50 mM sodium chloride; and uses thereof.

Disclosed herein is a method of purifying proteins, in particular hemopexin, comprising passing a solution comprising hemopexin and other proteins through a mixed-mode cation exchange chromatography resin under conditions that promote selective binding of hemopexin to the resin, and eluting the bound hemopexin from the resin. The present disclosure also extends to compositions comprising purified hemopexin and uses thereof.

Provided herein are compositions and methods for the treatment of hemolysis in pulmonary tissue. Also provided herein are methods of purifying proteins including apo-transferrin, haptoglobin, hemopexin, and combinations thereof.